CLVS Clovis Oncology Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * MAHAFFY PATRICK J	2. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [ CLVS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) See Remarks
(Last)          (First)          (Middle) C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100	3. Date of Earliest Transaction (MM/DD/YYYY) 3/1/2021
(Street) BOULDER, CO 80301 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.23	3/1/2021		A		220000		(1)	3/1/2031	Common Stock	220000	$0.00	220000	D
Stock Option (right to buy)	$6.23	3/1/2021		A		80000		(2)	3/1/2031	Common Stock	80000	$0.00	80000	D
Stock Option (right to buy)	$6.23	3/1/2021		A		40000		(3)	3/1/2031	Common Stock	40000	$0.00	40000	D
Stock Option (right to buy)	$6.23	3/1/2021		A		40000		(4)	3/1/2031	Common Stock	40000	$0.00	40000	D

Explanation of Responses:
(1)	The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
(2)	The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020.
(3)	The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021.
(4)	The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021.

Remarks: President and Chief Executive Officer

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
MAHAFFY PATRICK J C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301	X		See Remarks

Signatures
/s/ Patrick J. Mahaffy		3/3/2021
**Signature of Reporting Person		Date